Health & bio
FDA greenlights Foundayo oral GLP-1 obesity pill
April 1: FDA clears Eli Lilly's orforglipron (Foundayo) for overweight and obese adults with comorbidities. No food or water restrictions, anytime dosing. ATTAIN-1 top-dose average 12.4% weight loss (~27.3 lb).
Primary sources · 2